Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Tablets 120 X 250 mg |
|
55637 | |
|
Tablets 60 x 500 mg |
|
Related information
Dosage
For metastatic castration-resistant prostate cancer (CRPC) is generally 1,000 mg once a day in combination with 5 mg prednisone treatment twice a day.
For metastatic hormone-sensitive prostate cancer (mHSPC) is generally 1,000 mg once a day. In combination with 5 mg prednisone treatment once a day.
Please refer to the license holder for further details.
Indications
* For the treatment of metastatic castration-resistant prostate cancer in combination with prednisone.
* For the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
Contra-Indications
* Hypersensitivity to the active substances or to any of the excipients
* Woman (especially a pregnant woman)
* Severe liver impairment
* In combination with Ra-223 (which is used to treat prostate cancer)
Special Precautions
Please refer to the license holder for further details.
Side Effects
Very common: Fluid in the legs or feet, low level of potassium in the blood, rise in liver function values, high blood pressure, urinary tract infection, diarrhea.
Common: High level of blood lipids, Chest pain, Irregular heartbeats (atrial fibrillation), Heart failure, Rapid heart rhythm, A severe infection called sepsis, Bone fractures, Indigestion, Blood in the urine, Rash.
Please refer to the license holder for further details.
Drug interactions
Please refer to the license holder for further details.
Pregnancy and Lactation
Please refer to the license holder for further details.
Overdose
Please refer to the license holder for further details.
